knowledge -WSS

knowledge

author：focus 2025-09-28 01:37:16 - browse：6

U.S. President Joe Biden stands with his fingers locked next to an US flag — politics coverage from STAT — President Biden's White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs.

WASHINGTON — The White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs, its latest effort to draw attention to the program in an election year.

The news is not controversial: The pharmaceutical companies that make the first ten drugs up for negotiation all submitted counteroffers. It’s an incremental step in the new program, which was created in 2022.

Earlier this year, Medicare sent its initial price offers to the companies. Neither the Biden administration nor the drug manufacturers have volunteered any information about the White House’s initial price offers or the counteroffers. The process is scheduled to end by Aug. 1.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Rise in cancer among younger people worries and puzzles doctors

WSS

Roche’s Alnylam deal shows drug firms interested in heart drugs

Timeline: How the deadly wildfires took over Maui day by day

After Optum profits sink, UnitedHealth makes changes

Biogen’s boardroom scandal saddles CEO with first crisis

Device maker Teleflex to acquire urology company for $600M

UHS says company favors patients whose insurance pays more

explore

knowledge

entertainment

How to save PrEP access — and even expand it

Biogen says it will cut costs by $700 million, slash 1,000 jobs

What does generative AI mean for health care? We asked experts

What it's like to live with paralysis for one psychologist

What does generative AI mean for health care? We asked experts

Be careful with at

Virginia high school admissions case could be legal follow

Illumina slashes 2023 revenue projections yet again

After affirmative action ruling, medical educators look to 'holistic review'

Roche’s Alnylam deal shows drug firms interested in heart drugs

explore

Dems pitch expanding Medicare power to negotiate drug prices

BMS, looking to build heart drug business, turns to AI for diagnosis

STAT Report: Patient voices and perspectives

Why patients can’t get everything they want on drug pricing

YouTube cracks down on misinformation on cancer treatment

Why patients can’t get everything they want on drug pricing

Wikipedia

knowledge

hotspot

knowledge